Patents by Inventor Brad D. Maxwell

Brad D. Maxwell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of APOL1 and methods of using same
    Patent number: 11866446
    Abstract: The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).
    Type: Grant
    Filed: August 26, 2021
    Date of Patent: January 9, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jun Myun Ahn, Samantha Angle, Michael Aaron Brodney, Jingrong Cao, John E. Cochran, Jon H. Come, Leslie A. Dakin, Elena Dolgikh, Brad D. Maxwell, Suganthini S. Nanthakumar, Hardwin O'Dowd, Jessica Howard Olsen, Timothy J. Senter, Akira Joseph Shimizu, Steven David Stone, Haoxuan Wang
  • MODULATORS OF ALPHA-1 ANTITRYPSIN
    Publication number: 20230265080
    Abstract: Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).
    Type: Application
    Filed: February 9, 2023
    Publication date: August 24, 2023
    Inventors: Upul Keerthi BANDARAGE, Cavan McKeon BLIGH, Michael John BOYD, Diane M. BOUCHER, Michael Aaron BRODNEY, Veronique DAMAGNEZ, Lev Tyler DEWEY FANNING, Mary Elizabeth ECCLES, Robert Francis FIMOGNARI, JR., Kevin James GAGNON, Pedro M. GARCIA BARRANTES, Simon GIROUX, Ronald Lee GREY, JR., Amy Beth HALL, Sarah Carol HOOD, Dennis James HURLEY, Joshua Kennedy HUSSEY, Mac Arthur JOHNSON, JR., Peter JONES, Sarathy KESAVAN, Adam LOOKER, Brad D. MAXWELL, John Patrick MAXWELL, Ales MEDEK, Mettachit NAVAMAL, Philippe Marcel NUHANT, Setu RODAY, Stefanie ROEPER, Rupa SAWANT, Yi SHI, Rebecca Jane SWETT, Qing TANG, Timothy Lewis TAPLEY, Stephen A. THOMSON, Michael WALDO, Jinwang XU, Kevin Michael COTTRELL
  • IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
    Publication number: 20230242535
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Application
    Filed: September 2, 2022
    Publication date: August 3, 2023
    Inventors: Jacques Banville, Roger Rémillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dubé, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • Modulators of alpha-1 antitrypsin
    Patent number: 11623924
    Abstract: Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: April 11, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Upul Keerthi Bandarage, Cavan McKeon Bligh, Michael John Boyd, Diane M. Boucher, Michael Aaron Brodney, Veronique Damagnez, Lev Tyler Dewey Fanning, Mary Elizabeth Eccles, Robert Francis Fimognari, Jr., Kevin James Gagnon, Pedro M. Garcia Barrantes, Simon Giroux, Ronald Lee Grey, Jr., Amy Beth Hall, Sarah Carol Hood, Dennis James Hurley, Joshua Kennedy Hussey, Mac Arthur Johnson, Jr., Peter Jones, Sarathy Kesavan, Adam Looker, Brad D. Maxwell, John Patrick Maxwell, Ales Medek, Mettachit Navamal, Philippe Marcel Nuhant, Setu Roday, Stefanie Roeper, Rupa Sawant, Yi Shi, Rebecca Jane Swett, Qing Tang, Timothy Lewis Tapley, Stephen A. Thomson, Michael Waldo, Jinwang Xu, Kevin Michael Cottrell
  • INHIBITORS OF APOL1 AND METHODS OF USING SAME
    Publication number: 20220106327
    Abstract: The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).
    Type: Application
    Filed: August 26, 2021
    Publication date: April 7, 2022
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Jun Myun AHN, Samantha ANGLE, Michael Aaron BRODNEY, Jingrong CAO, John E. COCHRAN, Jon H. COME, Leslie A. DAKIN, Elena DOLGIKH, Brad D. MAXWELL, Suganthini S. NANTHAKUMAR, Hardwin O'DOWD, Jessica Howard OLSEN, Timothy J. SENTER, Akira Joseph SHIMIZU, Steven David STONE, Haoxuan WANG
  • MODULATORS OF ALPHA-1 ANTITRYPSIN
    Publication number: 20210179587
    Abstract: Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).
    Type: Application
    Filed: October 4, 2019
    Publication date: June 17, 2021
    Inventors: Upul Keerthi BANDARAGE, Cavan McKeon BLIGH, Michael John BOYD, Diane M. BOUCHER, Michael Aaron BRODNEY, Veronique DAMAGNEZ, Lev Tyler DEWEY FANNING, Mary Elizabeth ECCLES, Robert Francis FIMOGNARI, JR., Kevin James GAGNON, Pedro M. GARCIA BARRANTES, Simon GIROUX, Ronald Lee GREY, JR., Amy Beth HALL, Sarah Carol HOOD, Dennis James HURLEY, Joshua Kennedy HUSSEY, Mac Arthur JOHNSON, JR., Peter JONES, Sarathy KESAVAN, Adam LOOKER, Brad D. MAXWELL, John Patrick MAXWELL, Ales MEDEK, Mettachit NAVAMAL, Philippe Marcel NUHANT, Setu RODAY, Stefanie ROEPER, Rupa SAWANT, Yi SHI, Rebecca Jane SWETT, Qing TANG, Timothy Lewis TAPLEY, Stephen A. THOMSON, Michael WALDO, Jinwang XU
  • Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation
    Patent number: 10822343
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: November 3, 2020
    Assignees: Bristol-Myers Squibb Company, Université de Montréal
    Inventors: Jacques Banville, Roger Remillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dube, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
    Publication number: 20200123160
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Application
    Filed: August 13, 2019
    Publication date: April 23, 2020
    Inventors: Jacques Banville, Roger Remillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dube, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation
    Patent number: 10428077
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: October 1, 2019
    Assignees: Bristol-Myers Squibb Company, Université de Montréal
    Inventors: Jacques Banville, Roger Remillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dube, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
    Publication number: 20180305376
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Application
    Filed: June 27, 2018
    Publication date: October 25, 2018
    Inventors: Jacques Banville, Roger Remillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dube, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
    Patent number: 10047103
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: August 14, 2018
    Assignees: Bristol-Myers Squibb Company, Universite de Montreal
    Inventors: Jacques Banville, Roger Remillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dube, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
    Publication number: 20170247395
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Application
    Filed: May 12, 2017
    Publication date: August 31, 2017
    Inventors: Jaques Banville, Roger Remillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dube, Julia Guy, Eldon Scott Priestly, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation
    Patent number: 9688695
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: June 27, 2017
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Jacques Banville, Roger Rémillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dubé, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
    Patent number: 9580422
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein R* is an isotopically labeled hydroxypropyl moiety.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: February 28, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yaofeng Cheng, Weiqi Chen, Brad D. Maxwell, Bach D. Tran, Jun Li
  • ISOTOPICALLY LABELED TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS
    Publication number: 20160257680
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein R* is an isotopically labeled hydroxypropyl moiety.
    Type: Application
    Filed: October 21, 2014
    Publication date: September 8, 2016
    Inventors: Yaofeng Cheng, Weiqi Chen, Brad D. Maxwell, Bach D. Tran, Jun Li
  • IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
    Publication number: 20150094297
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Application
    Filed: April 24, 2013
    Publication date: April 2, 2015
    Inventors: Jacques Banville, Roger Rèmillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dubé, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller